Charles River Laboratories International (NYSE:CRL) Earns Equal Weight Rating from Analysts at Barclays

Barclays initiated coverage on shares of Charles River Laboratories International (NYSE:CRL) in a research note issued to investors on Friday, Benzinga reports. The brokerage issued an equal weight rating and a $230.00 price target on the medical research company’s stock.

Several other brokerages have also issued reports on CRL. The Goldman Sachs Group began coverage on shares of Charles River Laboratories International in a report on Thursday, June 6th. They issued a buy rating and a $290.00 price objective on the stock. TD Cowen cut their target price on shares of Charles River Laboratories International from $260.00 to $228.00 and set a hold rating on the stock in a research note on Monday, May 13th. Mizuho initiated coverage on Charles River Laboratories International in a report on Friday, June 7th. They issued a neutral rating and a $235.00 price target for the company. Robert W. Baird lowered their price target on Charles River Laboratories International from $282.00 to $270.00 and set an outperform rating for the company in a report on Friday, May 10th. Finally, TheStreet raised Charles River Laboratories International from a c+ rating to a b- rating in a report on Friday, March 1st. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $254.50.

Charles River Laboratories International Trading Down 0.4 %

Shares of CRL stock opened at $206.58 on Friday. The company’s 50-day moving average price is $220.16 and its 200-day moving average price is $232.74. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. The stock has a market cap of $10.64 billion, a price-to-earnings ratio of 24.30, a PEG ratio of 1.95 and a beta of 1.40. Charles River Laboratories International has a twelve month low of $161.65 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. As a group, equities analysts predict that Charles River Laboratories International will post 11 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 1,304 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares in the company, valued at $5,282,953.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Hedge funds and other institutional investors have recently made changes to their positions in the stock. American Trust purchased a new position in Charles River Laboratories International during the 1st quarter valued at about $250,000. Cetera Advisors LLC increased its holdings in Charles River Laboratories International by 197.1% during the 1st quarter. Cetera Advisors LLC now owns 3,357 shares of the medical research company’s stock valued at $910,000 after acquiring an additional 2,227 shares in the last quarter. Cetera Investment Advisers increased its holdings in Charles River Laboratories International by 223.4% during the 1st quarter. Cetera Investment Advisers now owns 9,740 shares of the medical research company’s stock valued at $2,639,000 after acquiring an additional 6,728 shares in the last quarter. Atria Investments Inc increased its holdings in Charles River Laboratories International by 19.6% during the 1st quarter. Atria Investments Inc now owns 17,502 shares of the medical research company’s stock valued at $4,742,000 after acquiring an additional 2,873 shares in the last quarter. Finally, Sanibel Captiva Trust Company Inc. increased its holdings in Charles River Laboratories International by 64.7% during the 1st quarter. Sanibel Captiva Trust Company Inc. now owns 30,490 shares of the medical research company’s stock valued at $8,261,000 after acquiring an additional 11,974 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).